ArticleBMJ neurology open2026
Stroke reperfusion in Aotearoa New Zealand: 5-year trends and a comparison of stroke clot retrieval and non-stroke clot retrieval centre presenters.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous thrombolysis (IVT) and stroke clot retrieval (SCR) are effective stroke reperfusion treatments with historical underuse and reported access disparities. Aims: This study describes trends in stroke reperfusion treatment between 2020 and 2024 in New Zealand and compares outcomes between patients first presenting to SCR and non-SCR centres. Methods: This observational registry-study uses data from the National Stroke Register for patients receiving reperfusion therapy. Outcomes include treatment rates, time delays, mortality and complications. Results: In 2020, 1021 of 7333 (13.9%) patients who had an ischaemic stroke had reperfusion therapy, increasing to 1237 of 6867 (18.0%) in 2024 (p<0.001). The greatest increases in therapy rates were among non-SCR centre first presenters. IVT rates increased from 11.2% in 2020 to 12.4% in 2024 (p=0.038), with reduced rates of symptomatic intracranial haemorrhage (3.2% to 1.5%; p=0.0272) and day-7 mortality (8.5% to 5.6%; p<0.001). SCR rates increased from 5.3% in 2020 to 9.7% in 2024 (p<0.001), with no change in patient outcomes. Between 2020 and 2024, national median door-to-needle time increased from 60 to 74 min (p<0.001). Patients first presenting to SCR centres were more likely to be treated with IVT within 60 min (48.4% vs 31.7%; p<0.001; adjusted OR of 2.8 (95% CI 2.0 to 4.0)). Conclusion: New Zealand stroke reperfusion therapy rates are rising, especially at non-SCR centres, and outcomes following IVT are improving. IVT treatment delays are worsening suggesting more resources are needed to maintain workflow efficiencies as case complexity is rising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.